Monocyte-Macrophage Lineages in Cancer: Biology, Plasticity, and Therapeutic Targeting
DOI:
https://doi.org/10.66505/cbtt.v1i2.23Keywords:
myeloid cells, macrophages, tumor-associated macrophages, TAM, myeloid-derived suppressor cells, MDSC, myeloid reprogramming, tumor microenvironment, cancer immunotherapy, nanomedicineAbstract
Monocytes are highly plastic innate immune cells that serve as critical sentinels of host defense, tissue homeostasis, and inflammatory regulation. Beyond their canonical functions in phagocytosis, cytokine and chemokine production, and antigen presentation, monocytes play increasingly recognized roles in shaping the tumor ecosystem. In cancer, malignant cells and their associated stromal networks profoundly reprogram monocyte development, trafficking, and functional states, converting these cells from immune defenders into key facilitators of tumor initiation, progression, and therapeutic resistance. Upon infiltration into the tumor microenvironment (TME), circulating monocytes differentiate into heterogeneous populations of tumor-associated macrophages (TAMs) that support cancer cell survival, angiogenesis, immune suppression, and metastatic dissemination. Recent advances in single-cell transcriptomics, spatial profiling, lineage tracing, and high-dimensional cytometry have transformed our understanding of monocyte and macrophage biology, revealing previously unappreciated diversity in their ontogeny, phenotypic states, and context-dependent functions across tumor types and disease stages. These technologies have uncovered dynamic crosstalk between monocytes, TAMs, cancer cells, and other immune and stromal components, highlighting monocyte-derived populations as central regulators of the immunosuppressive TME. In this Review, we synthesize current insights into the functional heterogeneity of monocyte and macrophage subsets in cancer, emphasizing their roles in tumorigenesis, immune evasion, and therapeutic responses. We further discuss emerging therapeutic strategies aimed at targeting monocyte recruitment, differentiation, and effector functions, including macrophage reprogramming, depletion, and combinatorial approaches with immunotherapy. Collectively, these advances position monocytes and their progeny as both biomarkers and actionable targets, offering new opportunities to reshape the tumor immune landscape for durable cancer control.
References
1. Jakubzick C, Gautier EL, Gibbings SL, Sojka DK, Schlitzer A, Johnson TE, et al. Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. Immunity. 2013;39(3):599-610. doi:10.1016/j.immuni.2013.08.007
2. Lavin Y, Kobayashi S, Leader A, Amir ED, Elefant N, Bigenwald C, et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell. 2017;169(4):750-765.e17. doi:10.1016/j.cell.2017.04.014
3. Zilionis R, Engblom C, Pfirschke C, Savova V, Zemmour D, Saatcioglu HD, et al. Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity. 2019;50(5):1317-1334.e10. doi:10.1016/j.immuni.2019.03.009
4. Kiss M, Caro AA, Raes G, Laoui D. Systemic reprogramming of monocytes in cancer. Front Oncol. 2020;10:1399. doi:10.3389/fonc.2020.01399
5. Ugel S, Cane S, De Sanctis F, Bronte V. Monocytes in the tumor microenvironment. Annu Rev Pathol. 2021;16:93-122. doi:10.1146/annurev-pathmechdis-012418-013058
6. Chen X, Li Y, Xia H, Chen YH. Monocytes in tumorigenesis and tumor immunotherapy. Cells. 2023;12(13):1673. doi:10.3390/cells12131673
7. Cassetta L, Pollard JW. A timeline of tumour-associated macrophage biology. Nat Rev Cancer. 2023;23(4):238-257. doi:10.1038/s41568-022-00547-1
8. Han J, Dong L, Wu M, Ma F. Dynamic polarization of tumor associated macrophages and their interaction with intratumoral T cells in an inflamed tumor microenvironment: from mechanistic insights to therapeutic opportunities. Front Immunol. 2023;14:1160340. doi:10.3389/fimmu.2023.1160340
9. Colak S, ten Dijke P. Targeting TGF-β signaling in cancer. Trends Cancer. 2017;3(1):56-71. doi:10.1016/j.trecan.2016.11.008
10. Kim J, Bae JS. Tumor associated macrophages and neutrophils in tumor microenvironment. Mediators Inflamm. 2016;2016:6058147. doi:10.1155/2016/6058147
11. Bejarano L, Jordão MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 2021;11(4):933-959. doi:10.1158/2159-8290.cd-20-1808
12. De Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374-403. doi:10.1016/j.ccell.2023.02.016
13. Liu L, Li Y, Li B. Interactions between cancer cells and tumor-associated macrophages in tumor microenvironment. Biochim Biophys Acta Rev Cancer. 2025;1880(3):189344. doi:10.1016/j.bbcan.2025.189344
14. Bischoff P, Trinks A, Obermayer B, Pett JP, Wiederspahn J, Uhlitz F, et al. Single-cell RNA sequencing reveals distinct tumor microenvironmental patterns in lung adenocarcinoma. Oncogene. 2021;40(50):6748-6758. doi:10.1038/s41388-021-02054-3
15. De Zuani M, Xue H, Park JS, Dentro SC, Seferbekova Z, Tessier J, et al. Single-cell and spatial transcriptomics analysis of non-small cell lung cancer. Nat Commun. 2024;15:4388. doi:10.1038/s41467-024-48700-8
16. Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 2018;17(12):887-904. doi:10.1038/nrd.2018.169
17. Li C, Xiao M, Geng S, Wang Y, Zeng L, Lai P, et al. Comprehensive analysis of human monocyte subsets using full-spectrum flow cytometry and hierarchical marker clustering. Front Immunol. 2024;15:1405249. doi:10.3389/fimmu.2024.1405249
18. Li M, Yang Y, Xiong L, Jiang P, Wang J, Li C. Metabolism, metabolites, and macrophages in cancer. J Hematol Oncol. 2023;16(1):80. doi:10.1186/s13045-023-01478-6
19. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000;164(12):6166-6173. doi:10.4049/jimmunol.164.12.6166
20. Denardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, et al. CD4+ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009;16(2):91-102. doi:10.1016/j.ccr.2009.06.018
21. Cassetta L, Fragkogianni S, Sims AH, Swierczak A, Forrester LM, Zhang H, et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell. 2019;35(4):588-602.e10. doi:10.1016/j.ccell.2019.02.009
22. Curtaz CJ, Schmitt C, Herbert SL, Feldheim J, Schlegel N, Gosselet F, et al. Serum-derived factors of breast cancer patients with brain metastases alter permeability of a human blood-brain barrier model. Fluids Barriers CNS. 2020;17(1):31. doi:10.1186/s12987-020-00192-6
23. Dehqanzada ZA, Storrer CE, Hueman MT, Foley RJ, Harris KA, Jama YH, et al. Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients. Clin Cancer Res. 2006;12(2):478-486. doi:10.1158/1078-0432.ccr-05-1425
24. Sanford DE, Belt BA, Panni RZ, Mayer A, Deshpande AD, Carpenter D, et al. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res. 2013;19(13):3404-3415. doi:10.1158/1078-0432.ccr-13-0525
25. Rannikko JH, Hollmen M. Clinical landscape of macrophage-reprogramming cancer immunotherapies. Br J Cancer. 2024;131(4):627-640. doi:10.1038/s41416-024-02715-6
26. Henze AT, Mazzone M. The impact of hypoxia on tumor-associated macrophages. J Clin Invest. 2016;126(10):3672-3679. doi:10.1172/jci84427
27. Karimova AF, Khalitova AR, Suezov R, Markov N, Mukhamedshina Y, Rizvanov AA, et al. Immunometabolism of tumor-associated macrophages: A therapeutic perspective. Eur J Cancer. 2025;220:115332. doi:10.1016/j.ejca.2025.115332
28. Wong KL, Tai JJ, Wong WC, Han H, Sem X, Yeap WH, et al. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood. 2011;118(5):e16-31. doi:10.1182/blood-2010-12-326355
29. Mulder K, Patel AA, Kong WT, Piot C, Halitzki E, Dunsmore G, et al. Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease. Immunity. 2021;54(8):1883-1900.e5. doi:10.1016/j.immuni.2021.07.007
30. Petty AJ, Yang Y. Tumor-associated macrophages: implications in cancer immunotherapy. Immunotherapy. 2017;9(3):289-302. doi:10.2217/imt-2016-0135
31. Li Z, Li J, Bai X, Huang X, Wang Q. Tumor microenvironment as a complex milieu driving cancer progression: a mini review. Clin Transl Oncol. 2025;27(5):1943-1952. doi:10.1007/s12094-024-03697-w
32. Albonici L, Giganti MG, Modesti A, Manzari V, Bei R. Multifaceted role of the placental growth factor (PlGF) in the antitumor immune response and cancer progression. Int J Mol Sci. 2019;20(12):2970. doi:10.3390/ijms20122970
33. Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125(Pt 23):5591-5596. doi:10.1242/jcs.116392
34. Kalbasi A, Komar C, Tooker GM, Liu M, Lee JW, Gladney WL, et al. Tumor-derived CCL2 mediates resistance to radiotherapy in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2017;23(1):137-148. doi:10.1158/1078-0432.ccr-16-0870
35. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16(11):2927-2931. doi:10.1158/1078-0432.ccr-09-2329
36. Pickup M, Novitskiy S, Moses HL. The roles of TGF-β in the tumour microenvironment. Nat Rev Cancer. 2013;13(11):788-799. doi:10.1038/nrc3603
37. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39-51. doi:10.1016/j.cell.2010.03.014
38. Cassetta L, Pollard JW. Cancer immunosurveillance: role of patrolling monocytes. Cell Res. 2016;26(1):3-4. doi:10.1038/cr.2015.144
39. Kitamura T, Qian BZ, Pollard JW. Immune cell promotion of metastasis. Nat Rev Immunol. 2015;15(2):73-86. doi:10.1038/nri3789
40. Khalaf K, Hana D, Chou JT, Singh C, Mackiewicz A, Kaczmarek M. Aspects of the tumor microenvironment involved in immune resistance and drug resistance. Front Immunol. 2021;12:656364. doi:10.3389/fimmu.2021.656364
41. Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018;19(2):108-119. doi:10.1038/s41590-017-0022-x
42. Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer. 2020;20(9):485-503. doi:10.1038/s41568-020-0281-y
43. Cox N, Pokrovskii M, Vicario R, Geissmann F. Origins, biology, and diseases of tissue macrophages. Annu Rev Immunol. 2021;39:313-344. doi:10.1146/annurev-immunol-093019-111748
44. Jahchan NS, Mujal AM, Pollack JL, Binnewies M, Sriram V, Reyno L, et al. Tuning the tumor myeloid microenvironment to fight cancer. Front Immunol. 2019;10:1611. doi:10.3389/fimmu.2019.01611
45. Woo SR, Corrales L, Gajewski TF. Innate immune recognition of cancer. Annu Rev Immunol. 2015;33:445-474. doi:10.1146/annurev-immunol-032414-112043
46. Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, Papneja N, Miller WH. A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol. 2020;27(Suppl 2):87-97. doi:10.3747/co.27.5223
47. Gren ST, Rasmussen TB, Janciauskiene S, Håkansson K, Gerwien JG, Grip O. A single-cell gene-expression profile reveals inter-cellular heterogeneity within human monocyte subsets. PLoS One. 2015;10(12):e0144351. doi:10.1371/journal.pone.0144351
48. Boyette LB, Macedo C, Hadi K, Elinoff BD, Walters JT, Ramaswami B, et al. Phenotype, function, and differentiation potential of human monocyte subsets. PLoS One. 2017;12(4):e0176460. doi:10.1371/journal.pone.0176460
49. Austermann J, Roth J, Barczyk-Kahlert K. The good and the bad: monocytes' and macrophages' diverse functions in inflammation. Cells. 2022;11(12):1979. doi:10.3390/cells11121979
50. Al-Khami AA, Zheng L, Del Valle L, Hossain F, Wyczechowska D, Zabaleta J, et al. Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells. Oncoimmunology. 2017;6(10):e1344804. doi:10.1080/2162402X.2017.1344804
51. Li J, Bolyard C, Xin G, Li Z. Targeting metabolic pathways of myeloid cells improves cancer immunotherapy. Front Cell Dev Biol. 2021;9:747863. doi:10.3389/fcell.2021.747863
52. Mantovani A, Marchesi F, Di Mitri D, Garlanda C. Macrophage diversity in cancer dissemination and metastasis. Cell Mol Immunol. 2024;21(11):1201-1214. doi:10.1038/s41423-024-01216-z
53. Wen S, Chen N, Hu Y, Huang L, Peng J, Yang M, et al. Elevated peripheral absolute monocyte count related to clinicopathological features and poor prognosis in solid tumors: systematic review, meta-analysis, and meta-regression. Cancer Med. 2021;10(5):1690-1714. doi:10.1002/cam4.3773
54. Kapoor G, Prakash S, Jaiswal V, Singh AK. Chronic inflammation and cancer: key pathways and targeted therapies. Cancer Invest. 2025;43(1):1-23. doi:10.1080/07357907.2024.2437614
55. Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6(1):263. doi:10.1038/s41392-021-00658-5
56. Oguma K, Oshima H, Oshima M. Inflammation, tumor necrosis factor and Wnt promotion in gastric cancer development. Future Oncol. 2010;6(4):515-526. doi:10.2217/fon.10.13
57. Yu L, Yuan J, Lou S, Huang A, Cai X, Ji J, et al. Factors affecting survival in patients with colorectal cancer: an umbrella review. J Transl Med. 2025;23:1185. doi:10.1186/s12967-025-06876-7
58. Wen J, Ye F, Huang X, Li S, Yang L, Xiao X, et al. Prognostic significance of preoperative circulating monocyte count in patients with breast cancer: based on a large cohort study. Medicine (Baltimore). 2015;94(49):e2266. doi:10.1097/md.0000000000002266
59. Shigeta K, Kosaka T, Kitano S, Yasumizu Y, Miyazaki Y, Mizuno R, et al. High absolute monocyte count predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy. Ann Surg Oncol. 2016;23(12):4115-4122. doi:10.1245/s10434-016-5354-5
60. Vajavaara H, Leivonen SK, Jørgensen J, Holte H, Leppä S. A low lymphocyte-to-monocyte ratio predicts poor outcome in high-risk aggressive large B-cell lymphoma. EJHaem. 2022;3(3):681-687. doi:10.1002/jha2.409
61. Mao Y, Chen D, Duan S, Zhao Y, Wu C, Zhu F, et al. Prognostic impact of pretreatment lymphocyte-to-monocyte ratio in advanced epithelial cancers: a meta-analysis. Cancer Cell Int. 2018;18:201. doi:10.1186/s12935-018-0698-5
62. Shibutani M, Maeda K, Nagahara H, Fukuoka T, Nakao S, Matsutani S, et al. The peripheral monocyte count is associated with the density of tumor-associated macrophages in the tumor microenvironment of colorectal cancer: a retrospective study. BMC Cancer. 2017;17(1):404. doi:10.1186/s12885-017-3395-1
63. Hayashi T, Fujita K, Nojima S, Hayashi Y, Nakano K, Ishizuya Y, et al. Peripheral blood monocyte count reflecting tumor-infiltrating macrophages is a predictive factor of adverse pathology in radical prostatectomy specimens. Prostate. 2017;77(14):1383-1388. doi:10.1002/pros.23398
64. de la Fuente J, Sharma A, Chari S, Majumder S. Peripheral blood monocyte counts are elevated in the pre-diagnostic phase of pancreatic cancer: A population based study. Pancreatology. 2019;19(8):1043-1048. doi:10.1016/j.pan.2019.10.002
65. Chen L, Qian J, Lin L, Lin J, Chen Q, Zhuang Z, et al. Prognostic value of preoperative lymphocyte-to-monocyte ratio in oral cancer patients and establishment of a dynamic nomogram. Oral Dis. 2021;27(5):1127-1136. doi:10.1111/odi.13629
66. Tham T, Olson C, Khaymovich J, Herman SW, Costantino PD. The lymphocyte-to-monocyte ratio as a prognostic indicator in head and neck cancer: a systematic review and meta-analysis. Eur Arch Otorhinolaryngol. 2018;275(7):1663-1670. doi:10.1007/s00405-018-4972-x
67. Barclay AN, Van den Berg TK. The interaction between signal regulatory protein alpha (SIRPalpha) and CD47: structure, function, and therapeutic target. Annu Rev Immunol. 2014;32:25-50. doi:10.1146/annurev-immunol-032713-120142
68. Chen YP, Kim HJ, Wu H, Price-Troska T, Villasboas JC, Jalali S, et al. SIRPalpha expression delineates subsets of intratumoral monocyte/macrophages with different functional and prognostic impact in follicular lymphoma. Blood Cancer J. 2019;9(10):84. doi:10.1038/s41408-019-0246-0
69. Patysheva M, Larionova I, Stakheyeva M, Grigoryeva E, Iamshchikov P, Tarabanovskaya N, et al. Effect of early-stage human breast carcinoma on monocyte programming. Front Oncol. 2021;11:800235. doi:10.3389/fonc.2021.800235
70. Kang SU, Cho SY, Jeong H, Han J, Chae HY, Yang H, et al. Matrix metalloproteinase 11 (MMP11) in macrophages promotes the migration of HER2-positive breast cancer cells and monocyte recruitment through CCL2-CCR2 signaling. Lab Invest. 2022;102(4):376-390. doi:10.1038/s41374-021-00699-y
71. Juusola M, Kuuliala K, Kuuliala A, Mustonen H, Vaha-Koskela M, Puolakkainen P, et al. Pancreatic cancer is associated with aberrant monocyte function and successive differentiation into macrophages with inferior anti-tumour characteristics. Pancreatology. 2021;21(2):397-405. doi:10.1016/j.pan.2020.12.025
72. Yin W, Lv J, Yao Y, Zhao Y, He Z, Wang Q, et al. Elevations of monocyte and neutrophils, and higher levels of granulocyte colony-stimulating factor in peripheral blood in lung cancer patients. Thorac Cancer. 2021;12(20):2680-2690. doi:10.1111/1759-7714.14103
73. Zhang B, Ye H, Ren X, Zheng S, Zhou Q, Chen C, et al. Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in pancreatic cancer. Cancer Lett. 2019;459:204-215. doi:10.1016/j.canlet.2019.06.005
74. Devalaraja S, To TKJ, Folkert IW, Natesan R, Alam MZ, Li M, et al. Tumor-derived retinoic acid regulates intratumoral monocyte differentiation to promote immune suppression. Cell. 2020;180(6):1098-1114.e16. doi:10.1016/j.cell.2020.02.042
75. Duluc D, Delneste Y, Tan F, Moles MP, Grimaud L, Lenoir J, et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood. 2007;110(13):4319-4330. doi:10.1182/blood-2007-02-072587
76. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med. 2008;205(10):2235-2249. doi:10.1084/jem.20080132
77. Michielon E, Lopez Gonzalez M, Burm JLA, Waaijman T, Jordanova ES, de Gruijl TD, et al. Micro-environmental cross-talk in an organotypic human melanoma-in-skin model directs M2-like monocyte differentiation via IL-10. Cancer Immunol Immunother. 2020;69(11):2319-2331. doi:10.1007/s00262-020-02626-4
78. Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21(8):485-498. doi:10.1038/s41577-020-00490-y
79. Li T, Li X, Zamani A, Wang W, Lee CN, Li M, et al. c-Rel is a myeloid checkpoint for cancer immunotherapy. Nat Cancer. 2020;1(5):507-517. doi:10.1038/s43018-020-0061-3
80. Waight JD, Netherby C, Hensen ML, Miller A, Hu Q, Liu S, et al. Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J Clin Invest. 2013;123(10):4464-4478. doi:10.1172/jci68189
81. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol. 2008;181(7):4666-4675. doi:10.4049/jimmunol.181.7.4666
82. Yan D, Wang J, Sun H, Zamani A, Zhang H, Chen W, et al. TIPE2 specifies the functional polarization of myeloid-derived suppressor cells during tumorigenesis. J Exp Med. 2020;217(2):e20182005. doi:10.1084/jem.20182005
83. Fultang N, Li X, Li T, Chen YH. Myeloid-derived suppressor cell differentiation in cancer: transcriptional regulators and enhanceosome-mediated mechanisms. Front Immunol. 2020;11:619253. doi:10.3389/fimmu.2020.619253
84. Li T, Bou-Dargham MJ, Fultang N, Li X, Pear WS, Sun H, et al. c-Rel-dependent monocytes are potent immune suppressor cells in cancer. J Leukoc Biol. 2022;112(4):845-859. doi:10.1002/jlb.1ma0422-518rr
85. Tumino N, Fiore PF, Pelosi A, Moretta L, Vacca P. Myeloid derived suppressor cells in tumor microenvironment: Interaction with innate lymphoid cells. Semin Immunol. 2022;61:101668. doi:10.1016/j.smim.2022.101668
86. Wu Y, Yi M, Niu M, Mei Q, Wu K. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol Cancer. 2022;21(1):184. doi:10.1186/s12943-022-01657-y
87. Peterlin P, Debord C, Eveillard M, Garnier A, Le Bourgeois A, Guillaume T, et al. Peripheral levels of monocytic myeloid-derived suppressive cells before and after first induction predict relapse and survivals in AML patients. J Cell Mol Med. 2022;26(21):5486-5492. doi:10.1111/jcmm.17576
88. Kajihara N, Kobayashi T, Otsuka R, Nio-Kobayashi J, Oshino T, Takahashi M, et al. Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer. Cancer Immunol Immunother. 2023;72(4):851-864. doi:10.1007/s00262-022-03293-3
89. Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K, et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood. 2021;137(19):2621-2633. doi:10.1182/blood.2020007445
90. Bayik D, Bartels CF, Lovrenert K, Watson DC, Zhang D, Kay K, et al. Distinct cell adhesion signature defines glioblastoma myeloid-derived suppressor cell subsets. Cancer Res. 2022;82(22):4274-4287. doi:10.1158/0008-5472.can-21-3840
91. Singh L, Muise ES, Bhattacharya A, Grein J, Javaid S, Stivers P, et al. ILT3 (LILRB4) promotes the immunosuppressive function of tumor-educated human monocytic myeloid-derived suppressor cells. Mol Cancer Res. 2021;19(4):702-716. doi:10.1158/1541-7786.mcr-20-0622
92. Su MT, Kumata S, Endo S, Okada Y, Takai T. LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs. Oncoimmunology. 2022;11(1):2060907. doi:10.1080/2162402X.2022.2060907
93. Arkhypov I, Ozbay Kurt FG, Bitsch R, Novak D, Petrova V, Lasser S, et al. HSP90alpha induces immunosuppressive myeloid cells in melanoma via TLR4 signaling. J Immunother Cancer. 2022;10:e005551. doi:10.1136/jitc-2022-005551
94. Alicea-Torres K, Sanseviero E, Gui J, Chen J, Veglia F, Yu Q, et al. Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway. Nat Commun. 2021;12(1):1717. doi:10.1038/s41467-021-22033-2
95. Zhan X, He Q, Sheng J, Jiang X, Lin L, Huang Y, et al. USP12 positively regulates M-MDSC function to inhibit antitumour immunity through deubiquitinating and stabilizing p65. Immunology. 2022;167(4):544-557. doi:10.1111/imm.13552
96. Alissafi T, Hatzioannou A, Mintzas K, Barouni RM, Banos A, Sormendi S, et al. Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells. J Clin Invest. 2018;128(9):3840-3852. doi:10.1172/jci120888
97. De Gassart A, Camosseto V, Thibodeau J, Ceppi M, Catalan N, Pierre P, et al. MHC class II stabilization at the surface of human dendritic cells is the result of maturation-dependent MARCH I down-regulation. Proc Natl Acad Sci U S A. 2008;105(9):3491-3496. doi:10.1073/pnas.0708874105
98. Liu M, Zhou J, Liu X, Feng Y, Yang W, Wu F, et al. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. Gut. 2020;69(2):365-379. doi:10.1136/gutjnl-2018-317257
99. Arihara F, Mizukoshi E, Kitahara M, Takata Y, Arai K, Yamashita T, et al. Increase in CD14+HLA-DR-/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol Immunother. 2013;62(8):1421-1430. doi:10.1007/s00262-013-1447-1
100. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475(7355):222-225. doi:10.1038/nature10138
101. Ikeda N, Asano K, Kikuchi K, Uchida Y, Ikegami H, Takagi R, et al. Emergence of immunoregulatory Ym1+Ly6Chi monocytes during recovery phase of tissue injury. Sci Immunol. 2018;3(28):eaat0207. doi:10.1126/sciimmunol.aat0207
102. Shibuya T, Kamiyama A, Sawada H, Kikuchi K, Maruyama M, Sawado R, et al. Immunoregulatory monocyte subset promotes metastasis associated with therapeutic intervention for primary tumor. Front Immunol. 2021;12:663115. doi:10.3389/fimmu.2021.663115
103. Sizemore S, Cicek M, Sizemore N, Ng KP, Casey G. Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin. Cancer Res. 2007;67(13):6183-6191. doi:10.1158/0008-5472.can-06-3575
104. Zhang Y, Zhao Q, Du J. Regulatory role of ezrin in esophageal cancer progression via the PI3K-AKT signaling pathway. Hereditas. 2025;162:199. doi:10.1186/s41065-025-00554-w
105. Gomez KE, Wu F, Keysar SB, Morton JJ, Miller B, Chimed TS, et al. Cancer cell CD44 mediates macrophage/monocyte-driven regulation of head and neck cancer stem cells. Cancer Res. 2020;80(19):4185-4198. doi:10.1158/0008-5472.can-20-1079
106. Chen Q, Zhang XH, Massague J. Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell. 2011;20(4):538-549. doi:10.1016/j.ccr.2011.08.025
107. Wang PC, Weng CC, Hou YS, Jian SF, Fang KT, Hou MF, et al. Activation of VCAM-1 and its associated molecule CD44 leads to increased malignant potential of breast cancer cells. Int J Mol Sci. 2014;15(3):3560-3579. doi:10.3390/ijms15033560
108. Arif AA, Huang YH, Freeman SA, Atif J, Dean P, Lai JCY, et al. Inflammation-induced metastatic colonization of the lung is facilitated by hepatocyte growth factor-secreting monocyte-derived macrophages. Mol Cancer Res. 2021;19(12):2096-2109. doi:10.1158/1541-7786.mcr-21-0009
109. Oh K, Lee OY, Shon SY, Nam O, Ryu PM, Seo MW, et al. A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model. Breast Cancer Res. 2013;15(5):R79. doi:10.1186/bcr3473
110. Ouzounova M, Lee E, Piranlioglu R, El Andaloussi A, Kolhe R, Demirci MF, et al. Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade. Nat Commun. 2017;8:14979. doi:10.1038/ncomms14979
111. Roberts LM, Perez MJ, Balogh KN, Mingledorff G, Cross JV, Munson JM. Myeloid derived suppressor cells migrate in response to flow and lymphatic endothelial cell interaction in the breast tumor microenvironment. Cancers (Basel). 2022;14(12):3008. doi:10.3390/cancers14123008
112. Cha YJ, Koo JS. Role of tumor-associated myeloid cells in breast cancer. Cells. 2020;9(8):1785. doi:10.3390/cells9081785
113. Benzing C, Lam H, Tsang CM, Rimmer A, Arroyo-Berdugo Y, Calle Y, et al. TIMP-2 secreted by monocyte-like cells is a potent suppressor of invadopodia formation in pancreatic cancer cells. BMC Cancer. 2019;19(1):1214. doi:10.1186/s12885-019-6429-z
114. Hagerling C, Gonzalez H, Salari K, Wang CY, Lin C, Robles I, et al. Immune effector monocyte-neutrophil cooperation induced by the primary tumor prevents metastatic progression of breast cancer. Proc Natl Acad Sci U S A. 2019;116(43):21704-21714. doi:10.1073/pnas.1907660116
115. Wang R, Bao W, Pal M, Liu Y, Yazdanbakhsh K, Zhong H. Intermediate monocytes induced by IFN-γ inhibit cancer metastasis by promoting NK cell activation through FOXO1 and interleukin-27. J Immunother Cancer. 2022;10(1):e003539. doi:10.1136/jitc-2021-003539
116. Hanna RN, Cekic C, Sag D, Tacke R, Thomas GD, Nowyhed H, et al. Patrolling monocytes control tumor metastasis to the lung. Science. 2015;350(6263):985-990. doi:10.1126/science.aac9407
117. Guedez L, Jensen-Taubman S, Bourboulia D, Kwityn CJ, Wei B, Caterina J, et al. TIMP-2 targets tumor-associated myeloid suppressor cells with effects in cancer immune dysfunction and angiogenesis. J Immunother. 2012;35(6):502-512. doi:10.1097/cji.0b013e3182619c8e
118. Schulz C, Perdiguero EG, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K, et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science. 2012;336(6077):86-90. doi:10.1126/science.1219179
119. van Furth R, Cohn ZA. The origin and kinetics of mononuclear phagocytes. J Exp Med. 1968;128(3):415-435. doi:10.1084/jem.128.3.415
120. Boutilier AJ, Elsawa SF. Macrophage polarization states in the tumor microenvironment. Int J Mol Sci. 2021;22(13):6995. doi:10.3390/ijms22136995
121. Fu LQ, Du WL, Cai MH, Yao JY, Zhao YY, Mou XZ. The roles of tumor associated macrophages in tumor angiogenesis and metastasis. Cell Immunol. 2020;353:104119. doi:10.1016/j.cellimm.2020.104119
122. Nielsen SR, Schmid MC. Macrophages as key drivers of cancer progression and metastasis. Mediators Inflamm. 2017;2017:9624760. doi:10.1155/2017/9624760
123. Komohara Y, Fujiwara Y, Ohnishi K, Takeya M. Tumor associated macrophages: potential therapeutic targets for anti cancer therapy. Adv Drug Deliv Rev. 2016;99(Pt B):180-185. doi:10.1016/j.addr.2015.11.009
124. Sica A, Saccani A, Mantovani A. Tumor-associated macrophages: a molecular perspective. Int Immunopharmacol. 2002;2(8):1045-1054. doi:10.1016/s1567-5769(02)00064-4
125. Lahmar Q, Keirsse J, Laoui D, Movahedi K, Van Overmeire E, Van Ginderachter JA. Tissue-resident versus monocyte-derived macrophages in the tumor microenvironment. Biochim Biophys Acta Rev Cancer. 2016;1865(1):23-34. doi:10.1016/j.bbcan.2015.06.009
126. Ammarah U, Pereira-Nunes A, Delfini M, Mazzone M. From monocyte-derived macrophages to resident macrophages-how metabolism leads their way in cancer. Mol Oncol. 2024;18(7):1739-1758. doi:10.1002/1878-0261.13618
127. Davies LC, Taylor PR. Tissue-resident macrophages: then and now. Immunology. 2015;144(4):541-548. doi:10.1111/imm.12451
128. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25(6):846-859. doi:10.1016/j.ccr.2014.05.016
129. Scott CL, Zheng F, De Baetselier P, Martens L, Saeys Y, De Prijck S, et al. Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells. Nat Commun. 2016;7:10321. doi:10.1038/ncomms10321
130. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14-20. doi:10.1016/j.immuni.2014.06.008
131. Bill R, Wirapati P, Messemaker M, Roh W, Zitti B, Duval F, et al. CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers. Science. 2023;381(6657):515-524. doi:10.1126/science.ade2292
132. Kadomoto S, Izumi K, Mizokami A. Macrophage polarity and disease control. Int J Mol Sci. 2021;23(1):144. doi:10.3390/ijms23010144
133. Su X, Liang C, Chen R, Duan S. Deciphering tumor microenvironment: CXCL9 and SPP1 as crucial determinants of tumor-associated macrophage polarity and prognostic indicators. Mol Cancer. 2024;23:13. doi:10.1186/s12943-023-01931-7
134. Zhu S, Luo Z, Li X, Han X, Shi S, Zhang T. Tumor-associated macrophages: role in tumorigenesis and immunotherapy implications. J Cancer. 2021;12(1):54-64. doi:10.7150/jca.49692
135. Canli Ö, Nicolas AM, Gupta J, Finkelmeier F, Goncharova O, Pesic M, et al. Myeloid cell-derived reactive oxygen species induce epithelial mutagenesis. Cancer Cell. 2017;32(6):869-883.e5. doi:10.1016/j.ccell.2017.11.004
136. Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med. 1999;5(7):828-831. doi:10.1038/10552
137. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41(1):49-61. doi:10.1016/j.immuni.2014.06.010
138. Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin. 2008;29(11):1275-1288. doi:10.1111/j.1745-7254.2008.00889.x
139. Geeraerts X, Bolli E, Fendt SM, Van Ginderachter JA. Macrophage metabolism as therapeutic target for cancer, atherosclerosis, and obesity. Front Immunol. 2017;8:289. doi:10.3389/fimmu.2017.00289
140. Oates TC, Moura PL, Cross S, Roberts K, Baum HE, Haydn-Smith KL, et al. Defining the proteomic landscape of cultured macrophages and their polarization continuum. Immunol Cell Biol. 2023;101(10):947-963. doi:10.1111/imcb.12687
141. Palma A, Jarrah AS, Tieri P, Cesareni G, Castiglione F. Gene regulatory network modeling of macrophage differentiation corroborates the continuum hypothesis of polarization states. Front Physiol. 2018;9:1659. doi:10.3389/fphys.2018.01659
142. Liu X, Liu Y, Qi Y, Huang Y, Hu F, Dong F, et al. Signal pathways involved in the interaction between tumor-associated macrophages/TAMs and glioblastoma cells. Front Oncol. 2022;12:822085. doi:10.3389/fonc.2022.822085
143. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162-174. doi:10.1038/nri2506
144. Cortese N, Soldani C, Franceschini B, Barbagallo M, Marchesi F, Torzilli G, et al. Macrophages in colorectal cancer liver metastases. Cancers (Basel). 2019;11(5):633. doi:10.3390/cancers11050633
145. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124(2):263-266. doi:10.1016/j.cell.2006.01.007
146. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008;8(8):618-631. doi:10.1038/nrc2444
147. Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol. 2009;9(4):259-270. doi:10.1038/nri2528
148. Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in the tumor microenvironment. Trends Immunol. 2012;33(3):119-126. doi:10.1016/j.it.2011.12.001
149. Cheng S, Li Z, Gao R, Xing B, Gao Y, Yang Y, et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell. 2021;184(3):792-809.e23. doi:10.1016/j.cell.2021.01.010
150. Coutant F, Pin JJ, Miossec P. Extensive phenotype of human inflammatory monocyte-derived dendritic cells. Cells. 2021;10(7):1663. doi:10.3390/cells10071663
151. van Vlerken-Ysla L, Tyurina YY, Kagan VE, Gabrilovich DI. Functional states of myeloid cells in cancer. Cancer Cell. 2023;41(3):490-504. doi:10.1016/j.ccell.2023.02.009
152. Villani AC, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science. 2017;356(6335):eaah4573. doi:10.1126/science.aah4573
153. Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019;572(7769):392-396. doi:10.1038/s41586-019-1456-0
154. Becht E, Giraldo NA, Germain C, de Reyniès A, Laurent-Puig P, Zucman-Rossi J, et al. Immune contexture, immunoscore, and malignant cell molecular subgroups for prognostic and theranostic classifications of cancers. Adv Immunol. 2016;130:95-190. doi:10.1016/bs.ai.2015.12.002
155. Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662-680. doi:10.1038/s41568-020-0285-7
156. Jinushi M, Chiba S, Yoshiyama H, Masutomi K, Kinoshita I, Dosaka-Akita H, et al. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci U S A. 2011;108(30):12425-12430. doi:10.1073/pnas.1106645108
157. Kuwada K, Kagawa S, Yoshida R, Sakamoto S, Ito A, Watanabe M, et al. The epithelial-to-mesenchymal transition induced by tumor-associated macrophages confers chemoresistance in peritoneally disseminated pancreatic cancer. J Exp Clin Cancer Res. 2018;37(1):307. doi:10.1186/s13046-018-0981-2
158. Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015;27(4):462-472. doi:10.1016/j.ccell.2015.02.015
159. De Palma M, Mazzieri R, Politi LS, Pucci F, Zonari E, Sitia G, et al. Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell. 2008;14(4):299-311. doi:10.1016/j.ccr.2008.09.004
160. Gubin MM, Esaulova E, Ward JP, Malkova ON, Runci D, Wong P, et al. High-dimensional analysis delineates myeloid and lymphoid compartment remodeling during successful immune-checkpoint cancer therapy. Cell. 2018;175(4):1014-1030.e19. doi:10.1016/j.cell.2018.09.030
161. Xiao M, Li X. The impact of the tumor microenvironment on macrophages. Front Immunol. 2025;16:1572764. doi:10.3389/fimmu.2025.1572764
162. Movahedi K, Laoui D, Gysemans C, Baeten M, Stangé G, Van den Bossche J, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010;70(14):5728-5739. doi:10.1158/0008-5472.can-09-4672
163. Lebegge E, Arnouk SM, Bardet PMR, Kiss M, Raes G, Van Ginderachter JA. Innate immune defense mechanisms by myeloid cells that hamper cancer immunotherapy. Front Immunol. 2020;11:1395. doi:10.3389/fimmu.2020.01395
164. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4(1):71-78. doi:10.1038/nrc1256
165. Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One. 2012;7(12):e50946. doi:10.1371/journal.pone.0050946
166. Donkor MK, Lahue E, Hoke TA, Shafer LR, Coskun U, Solheim JC, et al. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells. Int Immunopharmacol. 2009;9(7):937-948. doi:10.1016/j.intimp.2009.03.021
167. Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, Ochoa JB, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med. 2005;202(7):931-939. doi:10.1084/jem.20050715
168. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073-1081. doi:10.1093/carcin/bgp127
169. Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol. 2009;27:669-692. doi:10.1146/annurev.immunol.021908.132557
170. Zhang J, Cao J, Ma S, Dong R, Meng W, Ying M, et al. Tumor hypoxia enhances non-small cell lung cancer metastasis by selectively promoting macrophage M2 polarization through the activation of ERK signaling. Oncotarget. 2014;5(20):9664-9677. doi:10.18632/oncotarget.1856
171. Ohtaki Y, Ishii G, Nagai K, Ashimine S, Kuwata T, Hishida T, et al. Stromal macrophage expressing CD204 is associated with tumor aggressiveness in lung adenocarcinoma. J Thorac Oncol. 2010;5(10):1507-1515. doi:10.1097/jto.0b013e3181eba692
172. Hirayama S, Ishii G, Nagai K, Ono S, Kojima M, Yamauchi C, et al. Prognostic impact of CD204-positive macrophages in lung squamous cell carcinoma: possible contribution of Cd204-positive macrophages to the tumor-promoting microenvironment. J Thorac Oncol. 2012;7(12):1790-1797. doi:10.1097/jto.0b013e3182745968
173. Cai H, Zhang Y, Wang J, Gu J. Defects in macrophage reprogramming in cancer therapy: the negative impact of PD-L1/PD-1. Front Immunol. 2021;12:690869. doi:10.3389/fimmu.2021.690869
174. Xu C, Xia Y, Zhang BW, Drokow EK, Li HY, Xu S, et al. Macrophages facilitate tumor cell PD-L1 expression via an IL-1β-centered loop to attenuate immune checkpoint blockade. MedComm (2020). 2023;4(2):e242. doi:10.1002/mco2.242
175. Conte E. Targeting monocytes/macrophages in fibrosis and cancer diseases: Therapeutic approaches. Pharmacol Ther. 2022;234:108031. doi:10.1016/j.pharmthera.2021.108031
176. Tan SN, Hao J, Ge J, Yang Y, Liu L, Huang J, et al. Regulatory T cells converted from Th1 cells in tumors suppress cancer immunity via CD39. J Exp Med. 2025;222(4):e20240445. doi:10.1084/jem.20240445
177. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 2011;475(7355):226-230. doi:10.1038/nature10169
178. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942-949. doi:10.1038/nm1093
179. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med. 2003;198(12):1875-1886. doi:10.1084/jem.20030152
180. Kuehnemuth B, Piseddu I, Wiedemann GM, Lauseker M, Kuhn C, Hofmann S, et al. CCL1 is a major regulatory T cell attracting factor in human breast cancer. BMC Cancer. 2018;18(1):1278. doi:10.1186/s12885-018-5117-8
181. Lv Q, Zhang Y, Gao W, Wang J, Hu Y, Yang H, et al. CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer. Pharmacol Res. 2024;202:107126. doi:10.1016/j.phrs.2024.107126
182. Wang J, Wu W, Yuan T, Wang L, Zang L, Liu Q, et al. Tumor-associated macrophages and PD-L1 in prostate cancer: a possible key to unlocking immunotherapy efficacy. Aging (Albany NY). 2024;16(1):445-465. doi:10.18632/aging.205378
183. Guo F, Kong W, Li D, Zhao G, Anwar M, Xia F, et al. M2-type tumor-associated macrophages upregulated PD-L1 expression in cervical cancer via the PI3K/AKT pathway. Eur J Med Res. 2024;29(1):357. doi:10.1186/s40001-024-01897-2
184. Guo F, Feng YC, Zhao G, Zhang R, Cheng ZZ, Kong WN, et al. Tumor-associated CD163+ M2 macrophage infiltration is highly associated with PD-L1 expression in cervical cancer. Cancer Manag Res. 2020;12:5831-5843. doi:10.2147/cmar.s257692
185. Deng R, Lu J, Liu X, Peng XH, Wang J, Li XP. PD-L1 Expression is highly associated with tumor-associated macrophage infiltration in nasopharyngeal carcinoma. Cancer Manag Res. 2020;12:11585-11596. doi:10.2147/cmar.s274913
186. Vonderheide RH, Burg JM, Mick R, Trosko JA, Li D, Shaik MN, et al. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology. 2013;2(1):e23033. doi:10.4161/onci.23033
187. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331(6024):1612-1616. doi:10.1126/science.1198443
188. Li DK, Wang W. Characteristics and clinical trial results of agonistic anti-CD40 antibodies in the treatment of malignancies. Oncol Lett. 2020;20(5):176. doi:10.3892/ol.2020.12037
189. Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res. 2007;13(4):1083-1088. doi:10.1158/1078-0432.ccr-06-1893
190. Hassan SB, Sørensen JF, Olsen BN, Pedersen AE. Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. Immunopharmacol Immunotoxicol. 2014;36(2):96-104. doi:10.3109/08923973.2014.890626
191. Djureinovic D, Wang M, Kluger HM. Agonistic CD40 antibodies in cancer treatment. Cancers (Basel). 2021;13(6):1302. doi:10.3390/cancers13061302
192. Labiano S, Roh V, Godfroid C, Hiou-Feige A, Romero J, Sum E, et al. CD40 agonist targeted to fibroblast activation protein α synergizes with radiotherapy in murine HPV-positive head and neck tumors. Clin Cancer Res. 2021;27(14):4054-4065. doi:10.1158/1078-0432.ccr-20-4717
193. Lum HD, Buhtoiarov IN, Schmidt BE, Berke G, Paulnock DM, Sondel PM, et al. In vivo CD40 ligation can induce T cell-independent antitumor effects that involve macrophages. J Leukoc Biol. 2006;79(6):1181-1192. doi:10.1189/jlb.0405191
194. Zhu GQ, Tang YL, Li L, Zheng M, Jiang J, Li XY, et al. Hypoxia inducible factor 1α and hypoxia inducible factor 2α play distinct and functionally overlapping roles in oral squamous cell carcinoma. Clin Cancer Res. 2010;16(19):4732-4741. doi:10.1158/1078-0432.ccr-10-1408
195. Tekin D, Dursun AD, Baştuğ M, Karaorman G, Fıçıcılar H. The effects of acute and intermittent hypoxia on the expressions of HIF-1α and VEGF in the left and right ventricles of the rabbit heart. Anadolu Kardiyol Derg. 2011;11(5):379-385. doi:10.5152/akd.2011.104
196. Davis L, Recktenwald M, Hutt E, Fuller S, Briggs M, Goel A, et al. Targeting HIF-2α in the tumor microenvironment: redefining the role of HIF-2α for solid cancer therapy. Cancers (Basel). 2022;14(5):1259. doi:10.3390/cancers14051259
197. Chouaib S, Messai Y, Couve S, Escudier B, Hasmim M, Noman MZ. Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front Immunol. 2012;3:21. doi:10.3389/fimmu.2012.00021
198. Xia W, Zhang X, Wang Y, Huang Z, Guo X, Fang L. Progress in targeting tumor-associated macrophages in cancer immunotherapy. Front Immunol. 2025;16:1658795. doi:10.3389/fimmu.2025.1658795
199. Liang D, Liu L, Zhao Y, Luo Z, He Y, Li Y, et al. Targeting extracellular matrix through phytochemicals: a promising approach of multi-step actions on the treatment and prevention of cancer. Front Pharmacol. 2023;14:1186712. doi:10.3389/fphar.2023.1186712
200. Lu P, Takai K, Weaver VM, Werb Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol. 2011;3(12):a005058. doi:10.1101/cshperspect.a005058
201. Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, Daly L, et al. The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia. 2013;15(7):848-862. doi:10.1593/neo.13706
202. Huang SP, Wu MS, Shun CT, Wang HP, Lin MT, Kuo ML, et al. Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. J Biomed Sci. 2004;11(4):517-527. doi:10.1007/bf02256101
203. Yang M, Wang L, Wang X, Wang X, Yang Z, Li J. IL-6 promotes FSH-induced VEGF expression through JAK/STAT3 signaling pathway in bovine granulosa cells. Cell Physiol Biochem. 2017;44(1):293-302. doi:10.1159/000484885
204. Cho JH, Lee HJ, Ko HJ, Yoon BI, Choe J, Kim KC, et al. The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma. Oncotarget. 2017;8(15):24932-24948. doi:10.18632/oncotarget.15326
205. Figueiredo P, Lepland A, Scodeller P, Fontana F, Torrieri G, Tiboni M, et al. Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy. Acta Biomater. 2021;133:231-243. doi:10.1016/j.actbio.2020.09.038
206. Liu CY, Xu JY, Shi XY, Huang W, Ruan TY, Xie P, et al. M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway. Lab Invest. 2013;93(7):844-854. doi:10.1038/labinvest.2013.69
207. Kwajah MM, Schwarz H. CD137 ligand signaling induces human monocyte to dendritic cell differentiation. Eur J Immunol. 2010;40(7):1938-1949. doi:10.1002/eji.200940105
208. Bartkowiak T, Curran MA. 4-1BB Agonists: multi-potent potentiators of tumor immunity. Front Oncol. 2015;5:117. doi:10.3389/fonc.2015.00117
209. Sanchez-Paulete AR, Labiano S, Rodriguez-Ruiz ME, Azpilikueta A, Etxeberria I, Bolaños E, et al. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy. Eur J Immunol. 2016;46(3):513-522. doi:10.1002/eji.201445388
210. Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood. 2011;117(8):2423-2432. doi:10.1182/blood-2010-08-301945
211. Ito SE, Shirota H, Kasahara Y, Saijo K, Ishioka C. IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model. Cancer Immunol Immunother. 2017;66(11):1485-1496. doi:10.1007/s00262-017-2043-6
212. Liu M, Kuo F, Capistrano KJ, Kang D, Nixon BG, Shi W, et al. TGF-β suppresses type 2 immunity to cancer. Nature. 2020;587(7832):115-120. doi:10.1038/s41586-020-2836-1
213. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell. 2013;23(3):277-286. doi:10.1016/j.ccr.2013.02.013
214. Jaynes JM, Sable R, Ronzetti M, Bautista W, Knotts Z, Abisoye-Ogunniyan A, et al. Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses. Sci Transl Med. 2020;12(530):eaax6337. doi:10.1126/scitranslmed.aax6337
215. Georgoudaki AM, Prokopec KE, Boura VF, Hellqvist E, Sohn S, Östling J, et al. Reprogramming tumor associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep. 2016;15(9):2000-2011. doi:10.1016/j.celrep.2016.04.084
216. Puig-Kröger A, Sierra-Filardi E, Domínguez-Soto A, Samaniego R, Corcuera MT, Gómez-Aguado F, et al. Folate receptor β is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. Cancer Res. 2009;69(24):9395-9403. doi:10.1158/0008-5472.can-09-2050
217. Cresswell GM, Wang B, Kischuk EM, Broman MM, Alfar RA, Vickman RE, et al. Folate receptor beta designates immunosuppressive tumor-associated myeloid cells that can be reprogrammed with folate-targeted drugs. Cancer Res. 2021;81(3):671-684. doi:10.1158/0008-5472.can-20-1414
218. Yin M, Li X, Tan S, Zhou HJ, Ji W, Bellone S, et al. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. J Clin Invest. 2016;126(11):4157-4173. doi:10.1172/jci87252
219. Pan Y, Yu Y, Wang X, Zhang T. Tumor-associated macrophages in tumor immunity. Front Immunol. 2020;11:583084. doi:10.3389/fimmu.2020.583084
220. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436-444. doi:10.1038/nature07205
221. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006;25(3):315-322. doi:10.1007/s10555-006-9001-7
222. Ugel S, De Sanctis F, Mandruzzato S, Bronte V. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Invest. 2015;125(9):3365-3376. doi:10.1172/jci80006
223. Chen XJ, Wei WF, Wang ZC, Wang N, Guo CH, Zhou CF, et al. A novel lymphatic pattern promotes metastasis of cervical cancer in a hypoxic tumour-associated macrophage-dependent manner. Angiogenesis. 2021;24(3):549-565. doi:10.1007/s10456-020-09766-2
224. Fujikawa M, Koma YI, Hosono M, Urakawa N, Tanigawa K, Shimizu M, et al. Chemokine (C C motif) ligand 1 derived from tumor associated macrophages contributes to esophageal squamous cell carcinoma progression via CCR8 mediated Akt/proline rich Akt substrate of 40 kDa/mammalian target of rapamycin pathway. Am J Pathol. 2021;191(4):686-703. doi:10.1016/j.ajpath.2021.01.004
225. Jiang Y, You Y, Xie Y, Zhou S, Ma M, Han B. Large extracellular vesicles derived from LPS-preconditioned cardiomyocytes alleviate myocarditis via mediating macrophage polarization and modulating p38 MAPK pathway. Front Immunol. 2025;16:1629676. doi:10.3389/fimmu.2025.1629676
226. Kumar A, Gupta P, Rana M, Chandra T, Dikshit M, Barthwal MK. Role of pyruvate kinase M2 in oxidized LDL-induced macrophage foam cell formation and inflammation. J Lipid Res. 2020;61(3):351-364. doi:10.1194/jlr.ra119000382
227. Tan Z, Xie N, Cui H, Moellering DR, Abraham E, Thannickal VJ, et al. Pyruvate dehydrogenase kinase 1 participates in macrophage polarization via regulating glucose metabolism. J Immunol. 2015;194(12):6082-6089. doi:10.4049/jimmunol.1402469
228. Yang H, Zhang Q, Xu M, Wang L, Chen X, Feng Y, et al. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis. Mol Cancer. 2020;19(1):41. doi:10.1186/s12943-020-01165-x
229. Opdenakker G, Van Damme J. Cytokines and proteases in invasive processes: molecular similarities between inflammation and cancer. Cytokine. 1992;4(4):251-258. doi:10.1016/1043-4666(92)90064-x
230. Fein MR, He XY, Almeida AS, Bruzas E, Pommier A, Yan R, et al. Cancer cell CCR2 orchestrates suppression of the adaptive immune response. J Exp Med. 2020;217(10):e20181551. doi:10.1084/jem.20181551
231. Ma Y, Mattarollo SR, Adjemian S, Yang H, Aymeric L, Hannani D, et al. CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. Cancer Res. 2014;74(2):436-445. doi:10.1158/0008-5472.can-13-1265
232. Fei L, Ren X, Yu H, Zhan Y. Targeting the CCL2/CCR2 axis in cancer immunotherapy: one stone, three birds? Front Immunol. 2021;12:771210. doi:10.3389/fimmu.2021.771210
233. Arwert EN, Harney AS, Entenberg D, Wang Y, Sahai E, Pollard JW, et al. A unidirectional transition from migratory to perivascular macrophage is required for tumor cell intravasation. Cell Rep. 2018;23(5):1239-1248. doi:10.1016/j.celrep.2018.04.007
234. Hu WM, Li M, Ning JZ, Tang YQ, Song TB, Li LZ, et al. FAM171B stabilizes vimentin and enhances CCL2-mediated TAM infiltration to promote bladder cancer progression. J Exp Clin Cancer Res. 2023;42:290. doi:10.1186/s13046-023-02860-5
235. Ren Z, Xu Z, Chang X, Liu J, Xiao W. STC1 competitively binding βPIX enhances melanoma progression via YAP nuclear translocation and M2 macrophage recruitment through the YAP/CCL2/VEGFA/AKT feedback loop. Pharmacol Res. 2024;204:107218. doi:10.1016/j.phrs.2024.107218
236. Zhang F, Li P, Liu S, Yang M, Zeng S, Deng J, et al. β-Catenin-CCL2 feedback loop mediates crosstalk between cancer cells and macrophages that regulates breast cancer stem cells. Oncogene. 2021;40(39):5854-5865. doi:10.1038/s41388-021-01986-0
237. Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, Kantari-Mimoun C, et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proc Natl Acad Sci U S A. 2018;115(17):E4041-4050. doi:10.1073/pnas.1720948115
238. Yu X, Wang D, Wang X, Sun S, Zhang Y, Wang S, et al. CXCL12/CXCR4 promotes inflammation-driven colorectal cancer progression through activation of RhoA signaling by sponging miR-133a-3p. J Exp Clin Cancer Res. 2019;38(1):32. doi:10.1186/s13046-018-1014-x
239. Tang C, Lei X, Xiong L, Hu Z, Tang B. HMGA1B/2 transcriptionally activated-POU1F1 facilitates gastric carcinoma metastasis via CXCL12/CXCR4 axis-mediated macrophage polarization. Cell Death Dis. 2021;12(5):422. doi:10.1038/s41419-021-03703-x
240. Roca H, Varsos ZS, Sud S, Craig MJ, Ying C, Pienta KJ. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem. 2009;284(49):34342-34354. doi:10.1074/jbc.m109.042671
241. Bonapace L, Coissieux M-M, Wyckoff J, Mertz KD, Varga Z, Junt T, et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature. 2014;515(7525):130-133. doi:10.1038/nature13862
242. Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, et al. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat. 2011;128(3):703-711. doi:10.1007/s10549-010-1154-y
243. Yin JZ, Shi XQ, Wang MD, Du H, Zhao XW, Li B, et al. Arsenic trioxide elicits anti-tumor activity by inhibiting polarization of M2-like tumor-associated macrophages via Notch signaling pathway in lung adenocarcinoma. Int Immunopharmacol. 2023;117:109899. doi:10.1016/j.intimp.2023.109899
244. Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M, et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res. 2002;62(4):1093-1102. PMID:11861388
245. Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Lifshitz-Mercer B, et al. Elevated expression of the CC chemokine RANTES in advanced breast carcinoma. Cancer Res. 1999;59(18):4681-4687. PMID:10493525.
246. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol. 2013;229(2):176-185. doi:10.1002/path.4133
247. Nie Y, Huang H, Guo M, Chen J, Wu W, Li W, et al. Breast phyllodes tumors recruit and repolarize tumor associated macrophages via secreting CCL5 to promote malignant progression, which can be inhibited by CCR5 inhibition therapy. Clin Cancer Res. 2019;25(13):3873-3886. doi:10.1158/1078-0432.ccr-18-3421
248. Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8(1):70. doi:10.1038/s41392-023-01332-8
249. Taylor MA, Lee YH, Schiemann WP. Role of TGF-β and the tumor microenvironment during mammary tumorigenesis. Gene Expr. 2011;15(3):117-132. doi:10.3727/105221611x13176664479322
250. David CJ, Massagué J. Contextual determinants of TGF-β action in development, immunity and cancer. Nat Rev Mol Cell Biol. 2018;19(7):419-435. doi:10.1038/s41580-018-0007-0
251. Xie F, Ling L, Van Dam H, Zhou F, Zhang L. TGF-β signaling in cancer metastasis. Acta Biochim Biophys Sin (Shanghai). 2018;50(1):121-132. doi:10.1093/abbs/gmx123
252. Bai X, Yi M, Jiao Y, Chu Q, Wu K, et al. Blocking TGF β signaling to enhance the efficacy of immune checkpoint inhibitor. Onco Targets Ther. 2019;12:9527-9538. doi:10.2147/ott.s224013
253. Batlle E, Massagué J. Transforming growth factor-β signaling in immunity and cancer. Immunity. 2019;50(4):924-940. doi:10.1016/j.immuni.2019.03.024
254. Lonning S, Mannick J, McPherson JM. Antibody targeting of TGF β in cancer patients. Curr Pharm Biotechnol. 2011;12(12):2176-2189. doi:10.2174/138920111798808392
255. Gigante M, Gesualdo L, Ranieri E. TGF-β: a master switch in tumor immunity. Curr Pharm Des. 2012;18(27):4126-4134. doi:10.2174/138161212802430378
256. Zhang S, Che D, Yang F, Chi C, Meng H, Shen J, et al. Tumor-associated macrophages promote tumor metastasis via the TGF-β/SOX9 axis in non-small cell lung cancer. Oncotarget. 2017;8:99801-99815. doi:10.18632/oncotarget.21068
257. Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009;69(5):2000-2009. doi:10.1158/0008-5472.can-08-2360
258. Schraufstatter IU, Zhao M, Khaldoyanidi SK, DiScipio RG. The chemokine CCL18 causes maturation of cultured monocytes to macrophages in the M2 spectrum. Immunology. 2012;135(4):287-298. doi:10.1111/j.1365-2567.2011.03541.x
259. Jafarzadeh A, Fooladseresht H, Minaee K, Bazrafshani MR, Khosravimashizi A, Nemati M, et al. Higher circulating levels of chemokine CCL22 in patients with breast cancer: evaluation of the influences of tumor stage and chemokine gene polymorphism. Tumour Biol. 2015;36(2):1163-1171. doi:10.1007/s13277-014-2739-6
260. Sánchez-Martín L, Estecha A, Samaniego R, Sánchez-Ramón S, Vega M, Sánchez-Mateos P. The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. Blood. 2011;117(1):88-97. doi:10.1182/blood-2009-12-258186
261. Reed JR, Stone MD, Beadnell TC, Ryu Y, Griffin TJ, Schwertfeger KL. Fibroblast growth factor receptor 1 activation in mammary tumor cells promotes macrophage recruitment in a CX3CL1-dependent manner. PLoS One. 2012;7(9):e45877. doi:10.1371/journal.pone.0045877
262. Li Z, Xi J, Li B, Liu Y, Wang G, Yu B, et al. SHP-2-induced M2 polarization of tumor associated macrophages via IL-4 regulate colorectal cancer progression. Front Oncol. 2023;13:1027575. doi:10.3389/fonc.2023.1027575
263. Azambuja JH, Ludwig N, Yerneni SS, Braganhol E, Whiteside TL. Arginase-1+ exosomes from reprogrammed macrophages promote glioblastoma progression. Int J Mol Sci. 2020;21(11):3990. doi:10.3390/ijms21113990
264. Li X, Chen L, Peng X, Zhan X. Progress of tumor-associated macrophages in the epithelial-mesenchymal transition of tumor. Front Oncol. 2022;12:911410. doi:10.3389/fonc.2022.911410
265. Guo Y, Deng X, Wang S, Yuan Y, Guo Z, Hao H, et al. SILAC proteomics based on 3D cell spheroids unveils the role of RAC2 in regulating the crosstalk between triple-negative breast cancer cells and tumor-associated macrophages. Int J Biol Macromol. 2024;254:127639. doi:10.1016/j.ijbiomac.2023.127639
266. Piao H, Fu L, Wang Y, Liu Y, Wang Y, Meng X, et al. A positive feedback loop between gastric cancer cells and tumor-associated macrophage induces malignancy progression. J Exp Clin Cancer Res. 2022;41:174. doi:10.1186/s13046-022-02366-6
267. Sun Y, Qian Y, Chen C, Wang H, Zhou X, Zhai W, et al. Extracellular vesicle IL-32 promotes the M2 macrophage polarization and metastasis of esophageal squamous cell carcinoma via FAK/STAT3 pathway. J Exp Clin Cancer Res. 2022;41:145. doi:10.1186/s13046-022-02348-8
268. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006;42(6):717-727. doi:10.1016/j.ejca.2006.01.003
269. Hu Q, Wu G, Wang R, Ma H, Zhang Z, Xue Q. Cutting edges and therapeutic opportunities on tumor-associated macrophages in lung cancer. Front Immunol. 2022;13:1007812. doi:10.3389/fimmu.2022.1007812
270. Biragyn A, Longo DL. Neoplastic "Black Ops": cancer's subversive tactics in overcoming host defenses. Semin Cancer Biol. 2012;22(1):50-59. doi:10.1016/j.semcancer.2012.01.005
271. Qi Y, Chang Y, Wang Z, Chen L, Kong Y, Zhang P, et al. Tumor-associated macrophages expressing galectin-9 identify immunoevasive subtype muscle-invasive bladder cancer with poor prognosis but favorable adjuvant chemotherapeutic response. Cancer Immunol Immunother. 2019;68(12):2067-2080. doi:10.1007/s00262-019-02429-2
272. Davuluri GVN, Chen CC, Chiu YC, Tsai HW, Chiu HC, Chen YL, et al. Autophagy drives Galectin-1 secretion from tumor-associated macrophages facilitating hepatocellular carcinoma progression. Front Cell Dev Biol. 2021;9:741820. doi:10.3389/fcell.2021.741820
273. Jang JH, Kim DH, Lim JM, Lee JW, Jeong SJ, Kim KP, et al. Breast cancer cell-derived soluble CD44 promotes tumor progression by triggering macrophage IL1β production. Cancer Res. 2020;80(6):1342-1356. doi:10.1158/0008-5472.can-19-2288
274. Jiang M, Liu L, Huang W, Qi Y, Li Y, Li B. HMGB1-activated tumor-associated macrophages promote migration and invasion via NF-κB/IL-6 signaling in oral squamous cell carcinoma. Int Immunopharmacol. 2024;126:111200. doi:10.1016/j.intimp.2023.111200
275. Liang M, Chen X, Wang L, Qin L, Wang H, Sun Z, et al. Cancer-derived exosomal TRIM59 regulates macrophage NLRP3 inflammasome activation to promote lung cancer progression. J Exp Clin Cancer Res. 2020;39:176. doi:10.1186/s13046-020-01688-7
276. Peng G, Wang C, Wang H, Qu M, Dong K, Yu Y, et al. Gankyrin-mediated interaction between cancer cells and tumor-associated macrophages facilitates prostate cancer progression and androgen deprivation therapy resistance. Oncoimmunology. 2023;12(1):2173422. doi:10.1080/2162402X.2023.2173422
277. Dai Y, Ji Z, Liang H, Jiang M, Wang L, Bao X, et al. CD44v5 domain regulates crosstalk between TNBC cells and tumor-associated macrophages by enhancing the IL-4R/STAT3 axis. Cancer Sci. 2024;115(7):2235-2253. doi:10.1111/cas.16200
278. Geng Y, Fan J, Chen L, Zhang C, Qu C, Qian L, et al. A Notch-dependent inflammatory feedback circuit between macrophages and cancer cells regulates pancreatic cancer metastasis. Cancer Res. 2021;81(1):64-76. doi:10.1158/0008-5472.can-20-0256
279. Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 2006;108(1):19-24. doi:10.1016/j.acthis.2006.01.003
280. Yao Y, Ye H, Qi Z, Mo L, Yue Q, Baral A, et al. B7-H4 (B7x)-mediated cross-talk between glioma-initiating cells and macrophages via the IL6/JAK/STAT3 pathway lead to poor prognosis in glioma patients. Clin Cancer Res. 2016;22(11):2778-2790. doi:10.1158/1078-0432.ccr-15-0858
281. Che F, Heng X, Zhang H, Su Q, Zhang B, Chen Y, et al. Novel B7-H4-mediated crosstalk between human non-Hodgkin lymphoma cells and tumor-associated macrophages leads to immune evasion via secretion of IL-6 and IL-10. Cancer Immunol Immunother. 2017;66(6):717-729. doi:10.1007/s00262-017-1961-7
282. Yuan L, Ye J, Fan D. The B7-H4 gene induces immune escape partly via upregulating the PD-1/Stat3 pathway in non-small cell lung cancer. Hum Immunol. 2020;81(5):254-261. doi:10.1016/j.humimm.2020.02.004
283. Wang Y, Ge WL, Wang SJ, Liu YY, Zhang ZH, Hua Y, et al. MiR-548t-5p regulates pancreatic ductal adenocarcinoma metastasis through an IL-33-dependent crosstalk between cancer cells and M2 macrophages. Cell Cycle. 2024;23(2):169-187. doi:10.1080/15384101.2024.2309026
284. Wang Q, Sun Z, Guo J, Li H, Zhang J, Zhang B, et al. Tumor-derived exosomal LINC01812 induces M2 macrophage polarization to promote perineural invasion in cholangiocarcinoma. Cancer Lett. 2025;617:217596. doi:10.1016/j.canlet.2025.217596
285. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19(10):1264-1272. doi:10.1038/nm.3337
286. Sawa-Wejksza K, Kandefer-Szerszeń M. Tumor-associated macrophages as target for antitumor therapy. Arch Immunol Ther Exp (Warsz). 2018;66(2):97-111. doi:10.1007/s00005-017-0480-8
287. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol. 2008;66(1):1-9. doi:10.1016/j.critrevonc.2007.07.004
288. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. doi:10.3322/caac.21763
289. Shi D, Gao L, Wan XC, Li J, Tian T, Hu J, et al. Clinicopathologic features and abnormal signaling pathways in plasmablastic lymphoma: a multicenter study in China. BMC Med. 2022;20(1):483. doi:10.1186/s12916-022-02683-9
290. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321-330. doi:10.1038/nature21349
291. Dempke WCM, Fenchel K, Uciechowski P, Dale SP. Second- and third-generation drugs for immuno-oncology treatment: The more the better? Eur J Cancer. 2017;74:55-72. doi:10.1016/j.ejca.2017.01.001
292. Guo S, Chen X, Guo C, Wang W. Tumour-associated macrophages heterogeneity drives resistance to clinical therapy. Expert Rev Mol Med. 2022;24:e17. doi:10.1017/erm.2022.8
293. Zhang W, Wang M, Ji C, Liu X, Gu B, Dong T. Macrophage polarization in the tumor microenvironment: Emerging roles and therapeutic potentials. Biomed Pharmacother. 2024;177:116930. doi:10.1016/j.biopha.2024.116930
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Ramona Moles, Christian Owusu
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright
Authors publishing in Cancer Biome and Targeted Therapy retain full copyright of their work. By submitting a manuscript, authors grant the publisher (GCINC Press) a non-exclusive license to publish, distribute, and archive the article, and to identify itself as the original publisher.
License
All articles are published open access under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0).
https://creativecommons.org/licenses/by/4.0/. This license permits unrestricted use, distribution, reproduction, and adaptation in any medium, including for commercial purposes, provided that:
- Proper attribution is given to the original author(s) and source,
- A link to the license is provided, and
- Any changes made are clearly indicated.
Author Rights
Authors retain the right to:
- Use their article in future works (e.g., books, theses, lectures)
- Share and archive the final published version on institutional repositories or personal websites
- Adapt or translate their work, or authorize others to do so, with proper citation
Reuse by Third Parties
Content is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). Third parties may copy, redistribute, remix, transform, and build upon the material for any purpose, including commercial use, provided that appropriate credit is given to the original author(s).
Archiving and Preservation
All articles are made freely available immediately upon publication, without embargo. Cancer Biome and Targeted Therapy is hosted on the Open Journal Systems (OJS) platform, developed by the Public Knowledge Project (PKP). The journal participates in long-term digital preservation through the PKP Preservation Network (PKP PN) using the LOCKSS system. Authors are encouraged to self-archive in institutional repositories, disciplinary archives, and preprint servers in accordance with the license terms.
Funding data
-
National Institute of General Medical Sciences
Grant numbers P20GM144041
